Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jyong Biotech Ltd. Ordinary Shares (MENS)
USD2.29
+0.07 (+2.93%)
TW NASDAQ Healthcare Biotechnology
Address
23F‑3, No. 95, Section 1, Xintai 5th Road 221
New Taipei City, TW
New Taipei City, TW
CEO
Fu-Feng Kuo
Website
jyongbio.com
IPO
2025-06-17
CIK 1954488 ISIN KYG831161065
Description
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.29
+0.07 (+2.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
104.7K
Beta
2.27
Float Shares
28.06M
Free Float %
36.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | +4.76% | -3.08% | +2.80% | -91.91% | -44.30% | -78.24% | -78.24% | -78.24% | -78.24% | -78.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.29
Quality scores
Altman Z-Score
-1.91
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-61.2% Q4'25: -395.7% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +95.1% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%-4.0% ★ Q4'25: +103,626.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.40× Q4'25: -2.59× (vs Q2'24)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
974.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
17
-2 vs prev Q
New positions
4
Closed positions
6
Increased
10
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 258.8K -2.1K (-0.8%) | 556.3K -473.9K (-46.0%) | 0.36% -0.003 pp | 0.00% +0.000 pp | USD3.95 -45.6% | 2 qtrs — |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 64.2K -150.0 (-0.2%) | 138.1K -116.2K (-45.7%) | 0.09% 0.000 pp | 0.00% +0.000 pp | USD33.58 -93.6% | 3 qtrs — |
| 3 | UBS GROUP AG | 37.4K -108.3K (-74.3%) | 80.3K -495.0K (-86.0%) | 0.05% -0.151 pp | 0.00% 0.000 pp | USD4.08 -47.3% | 3 qtrs — |
| 4 | MILLENNIUM MANAGEMENT LLC | 14.6K -25.7K (-63.8%) | 31.4K -127.7K (-80.3%) | 0.02% -0.036 pp | 0.00% 0.000 pp | USD15.40 -86.0% | 3 qtrs — |
| 5 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 13.9K +13.9K (+100.0%) | 29.9K +29.9K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD2.15 +0.0% | 1 qtrs NEW |
| 6 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 13.2K +784.0 (+6.3%) | 28.3K -20.6K (-42.1%) | 0.02% +0.001 pp | 0.00% -0.002 pp | USD3.84 -44.0% | 2 qtrs — |
| 7 | TOWER RESEARCH CAPITAL LLC (TRC) | 11.7K +6.9K (+144.6%) | 25.2K +6.3K (+33.1%) | 0.02% +0.010 pp | 0.00% +0.000 pp | USD2.96 -27.4% | 3 qtrs — |
| 8 | HRT FINANCIAL LP | 11.8K +11.8K (+100.0%) | 25.0K +25.0K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD2.15 +0.0% | 4 qtrs — |
| 9 | MORGAN STANLEY | 6.3K -21.8K (-77.6%) | 13.5K -97.5K (-87.8%) | 0.01% -0.030 pp | 0.00% +0.000 pp | USD7.57 -71.6% | 3 qtrs — |
| 10 | BARCLAYS PLC | 5.2K +1.6K (+46.6%) | 11.2K -2.8K (-20.2%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD3.38 -36.4% | 2 qtrs — |
| 11 | JPMORGAN CHASE & CO | 5.7K -372.0 (-6.1%) | 10.8K -13.1K (-54.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.95 -45.6% | 2 qtrs — |
| 12 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.9K +178.0 (+4.8%) | 8.3K -6.3K (-42.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.87 -44.4% | 2 qtrs — |
| 13 | CITIGROUP INC | 2.8K -8.1K (-74.4%) | 6.0K -37.0K (-86.1%) | 0.00% -0.011 pp | 0.00% +0.000 pp | USD3.95 -45.6% | 2 qtrs — |
| 14 | BNP PARIBAS ARBITRAGE, SNC | 1.9K +581.0 (+44.7%) | 4.0K -1.1K (-21.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD27.88 -92.3% | 3 qtrs — |
| 15 | GF FUND MANAGEMENT CO. LTD. | 1.7K +184.0 (+12.3%) | 3.6K -2.3K (-38.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.75 -42.7% | 2 qtrs — |
| 16 | BELL INVESTMENT ADVISORS, INC | 473.00 +473.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.15 +0.0% | 1 qtrs NEW |
| 17 | ROYAL BANK OF CANADA | 266.00 +266.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.15 +0.0% | 1 qtrs NEW |
| 18 | — | — -14.0 (-100.0%) | — -55.0 (-100.0%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 19 | BANK OF AMERICA CORP /DE/ | — -23.2K (-100.0%) | — -91.6K (-100.0%) | 0.00% -0.032 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 20 | FARTHER FINANCE ADVISORS, LLC | — -204.0 (-100.0%) | — -806.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 21 | JANE STREET GROUP, LLC | — -69.6K (-100.0%) | — -274.8K (-100.0%) | 0.00% -0.097 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 22 | MAN GROUP PLC | — -14.2K (-100.0%) | — -56.2K (-100.0%) | 0.00% -0.020 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 23 | ADVISOR GROUP HOLDINGS, INC. | — -420.0 (-100.0%) | — -1.7K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 7 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 53.5K | 0.40% |
| 2 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 8.6K | 0.19% |
| 3 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.01% | 119.2K | 0.35% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 8.0K | 0.35% |
| 5 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 5.6K | 1.19% |
| 6 | iShares Biotechnology ETF IBB | 0.00% | 462.0K | 0.44% |
| 7 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.00% | 58.9K | 0.21% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
76.03M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fenglin Hsu | Chief Technology Officer & Director | — | — |
| Fu-Feng Kuo | Chief Executive Officer & Chairwoman of the Board | — | female |
| Wanwen Su | Chief Science Officer | — | female |
| Wei Zhang | Chief Financial Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MENS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
